Flowflex

COVID-19 Antigen Home Test

A rapid test for the detection of COVID-19 antigens in nasal specimens.

COVID-19 Rapid Test

ACON Laboratories, Inc. is the only legal manufacturer of the FDA EUA Flowflex COVID-19 Antigen Home Test.

Critical Information When & Where You Need It

The Flowflex COVID-19 Antigen Home Test is all you need to determine your family’s Covid-19 status, whether symptoms are present or not. Can be used on children as young as 2 years old. Get the convenience of Flowflex!

  • Affordable
  • Easy-to-Use Nasal Swab Test
  • Results in 15 minutes
  • Safe for children as young as 2 years old
  • For use with and without symptoms
Expiration Date Extension

As of April 20, 2022, the Flowflex COVID-19 Antigen Home Test has an extended expiration date that is 4 months beyond the date printed on the kit box. Please click here for more information.

Test Procedure Overview

This test procedure overview does not replace the package insert. Before you begin the test, it is important to read and follow the detailed instructions in the package insert.

Videos

Adult Testing

Adult Testing

Child Testing

Adult Testing

Resource Library

Flowflex™ COVID-19 Antigen Home Test documents available for download.

b

Flowflex Covid-19 Antigen Home Test Consumer Package Insert

b

Flowflex Covid-19 Antigen Home Test Consumer Package Insert (Spanish)

b

Flowflex Covid-19 Antigen Home Test Fact Sheet for Healthcare Professionals

b

Flowflex Covid-19 Antigen Home Test Healthcare Provider Package Insert

b

Flowflex Covid-19 Antigen Home Test Distributor Sell Sheet

b

Flowflex Covid-19 Antigen Home Test Quick Reference Instructions

Frequently Asked Questions

  • In the USA, this product has not been FDA cleared or approved; but has been authorized by FDA under an EUA;
  • This product has been authorized only for the detection of proteins from SARS- CoV-2, not for any other viruses or pathogens; and,
  • The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

For more information on EUAs please visit: https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization

For the most up to date information on COVID-19, please visit: www.cdc.gov/COVID19